Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal Consta at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder

Next Previous
Trial Profile

A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal Consta at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Pharmacokinetics; Registrational
  • Sponsors Luye Pharma Group

    • Most Recent Events

    • 29 May 2019 According to a Luye Pharma Group media release, the US Food and Drug Administration (FDA) has completed the filing review and accepted the filing of Rykindo's new drug application (NDA).
    • 28 Mar 2019 According to a Luye Pharma Group media release, based on the data of this study and two other supportive studies, the company has submitted a new drug application (NDA) to the U.S. Food and Drug Administration for Risperidone Extended Release Microspheres for Injection (LY03004) for the treatment of schizophrenia and/or schizoaffective disorders.
    • 30 Dec 2018 According to a Luye Pharma Group media release, based on the data of this study, the company has entered the final stage of New Drug Application (NDA) submissions to the US FDA for Risperidone Extended Release Microspheres for Injection (LY03004) for the treatment of schizophrenia and/or schizoaffective disorders, after previous positive pre-NDA meeting with the U.S. Food and Drug Administration (FDA) and subsequent related procedures.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top